American People News

News that affects American households

Health & Safety

FDA proposes making NAC a lawful dietary supplement ingredient after a safety review finds 'minimal' concern

FDA has used enforcement discretion for NAC supplements since 2022. Comments on the proposal, published November 17, are due January 19, 2027.

By Health & Safety Desk · · 3 min read

What it means for you

  • The FDA has proposed a rule that would let products containing N-acetyl-L-cysteine (NAC) be sold lawfully as dietary supplements. It is not yet in force.
  • The agency says NAC is now excluded from supplements because it was approved as a drug in 1963, before it was sold as one. Since 2022 it has used enforcement discretion for such products.
  • FDA's review of 41 studies found a "minimal" level of concern; gastrointestinal pain or discomfort, nausea, vomiting and rash were the effects most often reported.
  • Comments are open until January 19, 2027. FDA proposes that a final rule take effect as soon as it is published.

The Food and Drug Administration has proposed a rule that would let products containing N-acetyl-L-cysteine, known as NAC, be sold lawfully as dietary supplements. The proposal, published in the Federal Register on Tuesday, November 17, is the first use of the agency's power to exempt an ingredient that the law otherwise keeps out of supplements because it was approved as a drug first, according to the FDA. Comments are open until January 19, 2027. Until a final rule is published, nothing in the law changes.

The problem, as the FDA describes it, is one of timing. Federal law excludes from the definition of a dietary supplement any article that was approved as a new drug before it was marketed as a supplement or a food. NAC was approved as a drug on September 14, 1963, under the brand name Mucomyst, while the earliest supplement advertisement the agency knows of dates from 1991. When Congress defined dietary supplements in 1994, NAC therefore became ineligible, the FDA says, even though companies kept selling it as one for more than 30 years.

The agency restated that view several times, including in 2001, in 2010 and in July 2020 warning letters to companies selling hangover products. After two citizen petitions in 2021, it said in March 2022 that it was considering a rule to allow NAC in supplements, and in August 2022 it issued guidance saying it would use enforcement discretion for certain NAC products labeled as supplements until it either completed a rule allowing NAC or denied the petition's request for one. That policy still applies. If the rule is finalized, the FDA intends to withdraw the guidance.

What the safety review found

To decide whether to use the exemption, the FDA ran a systematic review of studies in which people took NAC by mouth, and had its methods and conclusions peer reviewed externally. It identified 41 studies of high confidence, with doses of up to 9,000 milligrams a day and durations of up to three years. One study found significantly more nausea among people taking NAC; most others reported no adverse events, or none that differed significantly from comparison groups, the proposal says. The effects most commonly reported were gastrointestinal pain or discomfort, nausea, vomiting and rash.

The agency rated the level of concern as "minimal" on a five-point scale developed by the National Toxicology Program, and concluded there is a reasonable expectation of safety for NAC in supplements. Products on the market most often recommend 600, 1,000 or 1,200 milligrams a day, within the range of the doses studied, the FDA says. The proposal deals with NAC's legal status; whether it suits a particular person is a question for their health care provider.

NAC's regulatory history, as set out in the FDA's November 17, 2026 proposal
DateEvent
September 14, 1963NAC approved as a new drug (Mucomyst)
August/September 1991Earliest supplement advertisement known to the FDA
1994Congress defines dietary supplements, which excludes NAC
July 2020FDA warning letters to hangover product sellers say NAC is excluded
March 31, 2022FDA answers two citizen petitions and says it is considering a rule
August 2022Guidance on enforcement discretion for NAC supplements
November 17, 2026Proposed rule published
January 19, 2027Comment deadline

What would change

The rule would create a new list of ingredients that are not excluded from the supplement definition, with NAC as its first entry. NAC products labeled as supplements would then be regulated as supplements and would have to meet all the rules that apply to them, including manufacturing standards; adulterated or misbranded products could face enforcement action. Because the rule would relieve a restriction, the FDA proposes that a final version take effect as soon as it is published.

Part of the exclusion's purpose, according to the FDA, is to protect incentives to develop new drugs. The agency says it has no reason to believe that allowing NAC supplements would affect drug development, noting that acetylcysteine is still approved as a drug, including an injectable antidote for acetaminophen overdose, and that a search found 832 clinical trials on the use of NAC as a drug while supplements stayed on sale. It asks for comment on that point. The agency did not estimate the rule's benefits and puts its costs, mainly for the few companies in the market to read the rule, at about $848 in present value.

Comments can be filed at regulations.gov under docket FDA-2025-N-2699 until 11:59 p.m. Eastern time on January 19, 2027.

Sources

  1. Rulemaking To Provide That N-acetyl-L-cysteine Is Not Excluded From the Dietary Supplement Definition (proposed rule, FR Doc. 2026-23351, 91 FR 73717) Food and Drug Administration, via the Federal Register (govinfo), November 17, 2026
  2. Guidance for Industry: Policy Regarding N-acetyl-L-cysteine U.S. Food and Drug Administration, August 1, 2022

Researched and drafted with AI assistance, then checked against the 2 sources above in a separate fact-check on November 18, 2026. Spotted an error? Tell us.